Interim Report September 1, 2018 - May 31, 2019
Company Announcement No 08, 2019
Solid sales growth and profitability in Q3, but reduced organic growth outlook for the year.
Attachment
Upcoming Life Sciences Events
- April 2024
- Pharma-Biotech Product & Company Valuation - An Introductory
- Basel: Swiss Biotech Day 2024
- London: BioTrinity 2024
Latest company news
SPEVIGO® approved for expanded indications in China and the US